Department of Cardiology, Oslo University Hospital, Ullevaal, Oslo, Norway.
Curr Med Res Opin. 2010 Apr;26(4):879-87. doi: 10.1185/03007991003635178.
Control of elevated blood pressure has been shown to reduce the risk of cardiovascular events. The angiotensin II receptor blocker (ARB), telmisartan, has been shown to provide effective 24-hour blood pressure control. Additional antihypertensive efficacy can be achieved by combining telmisartan with the thiazide diuretic hydrochlorothiazide (HCTZ).
To review the clinical data in combination therapy with telmisartan and HCTZ.
Search of Medline and Embase for published clinical studies using the keywords telmisartan and HCTZ.
The telmisartan/HCTZ combination provides significant reductions in blood pressure, effective 24-hour blood pressure control and is well-tolerated. Blood pressure reductions with this combination are greater than those achieved with either drug alone, and in comparative studies telmisartan/HCTZ is more effective than other ARB/HCTZ combinations. However, it should be noted that some of the combinations assessed used doses of the drugs that were commercially available at the time of the trial and not higher doses that have been shown to have greater antihypertensive efficacy.
The combination of telmisartan/HCTZ is an effective and well-tolerated treatment option for patients with hypertension.
控制血压升高已被证明可降低心血管事件的风险。血管紧张素 II 受体阻滞剂（ARB）替米沙坦已被证明可提供有效的 24 小时血压控制。通过将替米沙坦与噻嗪类利尿剂氢氯噻嗪（HCTZ）联合使用，可以实现额外的降压疗效。
回顾替米沙坦和 HCTZ 联合治疗的临床数据。
使用关键词替米沙坦和 HCTZ 在 Medline 和 Embase 上搜索已发表的临床研究。
替米沙坦/HCTZ 联合治疗可显著降低血压，有效控制 24 小时血压，且耐受性良好。与单独使用任何一种药物相比，该联合治疗可使血压降低更多，在比较研究中，替米沙坦/HCTZ 比其他 ARB/HCTZ 联合治疗更有效。然而，值得注意的是，评估的一些组合使用的是试验时可获得的药物剂量，而不是已证明具有更大降压疗效的更高剂量。
替米沙坦/HCTZ 联合治疗是高血压患者有效且耐受良好的治疗选择。
